QIANHAI HEALTH HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.033 HKD | 0.00% |
|
-8.33% | -10.81% |
| Mar. 15 | Qianhai Health's Loss Shrinks in 2023 | MT |
| Mar. 14 | Qianhai Health Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 283M 36.18M | Sales 2022 | 1.96B 250M | Capitalization | 149M 19.04M |
|---|---|---|---|---|---|
| Net income 2021 | - 0 | Net income 2022 | -234M -29.87M | EV / Sales 2021 | 0.47 x |
| Net Debt 2021 | 5.19M 662K | Net cash position 2022 | 625K 79.79K | EV / Sales 2022 | 0.08 x |
| P/E ratio 2021 |
-143
x | P/E ratio 2022 |
-0.64
x | Employees | 16 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 46.67% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -8.33% | ||
| 1 month | -5.71% | ||
| 3 months | +10.00% | ||
| 6 months | -21.43% | ||
| Current year | -10.81% |
1 week
0.03
0.04
1 month
0.030.04
Current year
0.020.04
1 year
0.020.08
3 years
0.020.15
5 years
0.020.28
10 years
0.0240.80
| Managers | Title | Age | Since |
|---|---|---|---|
Guan Chao Huang
CHM | Chairman | 49 | 19-04-11 |
Tak Yung Yip
DFI | Director of Finance/CFO | 43 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Li
BRD | Director/Board Member | 69 | 16-05-16 |
Chee Lap Yuen
BRD | Director/Board Member | 50 | 16-02-28 |
Kai Ben Chen
BRD | Director/Board Member | 38 | 21-09-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.033 | 0.00% | 147 000 |
| 24-04-18 | 0.033 | 0.00% | 405,000 |
| 24-04-17 | 0.033 | 0.00% | 18,000 |
| 24-04-16 | 0.033 | 0.00% | 0 |
| 24-04-15 | 0.033 | -8.33% | 1,837,500 |
Delayed Quote Hong Kong S.E., April 19, 2024 at 04:08 am EDT
More quotes
Qianhai Health Holdings Limited is an investment holding company principally engaged in the sourcing and wholesaling of American Ginseng. Along with subsidiaries, the Company operates its business through four segments. The Cultivated Ginseng segment is engaged in the purchasing and sale of cultivated American ginseng. The Wild Ginseng segment is engaged in the purchasing and sale of wild ginseng from the United States. The Ginseng Wine segment is engaged in the manufacturing and sale of ginseng wine. Its wine products include American wild ginseng brandy and American wild ginseng white spirit. The Others segment is engaged in the trading of other products, including dried cordyceps, dried cubilose, dried seafood and skin care products, among others.
Sector
Drug Retailers
| 1st Jan change | Capi. | |
|---|---|---|
| -10.81% | 7.14M | |
| -31.48% | 15.18B | |
| -41.56% | 9.47B | |
| -10.75% | 6.15B | |
| +6.59% | 6.04B | |
| -38.44% | 5.44B | |
| +2.34% | 4.86B | |
| +50.00% | 4.23B | |
| -13.27% | 3.55B | |
| -10.36% | 3.51B |
- Stock Market
- Equities
- 911 Stock
